#bharatbiotech #sarscov2 #sarscov2vaccine #covid19 #covaxin #partnership pic.twitter.com/dMUnarqj8n With this new funding ExcellGene expands on a collaboration with the team of Prof Jamie Triccas that started in early 2020 Exe began to produce Wuhan trimerie SARS-Cav-spike proteins in March 2020, and nquendy Alpha, Beta, Delta and recently, Onicran variants.
The Company delivered these antigens to its partners as highly purified stablised, trimeric spike proteins that had been angered for high-yield production, it said.
The new CEPI partnership is a great opportunity to showcase what is possible in the manufacturing of highly-complex antigen structures, consisting of computer-designed individual monomers, for a potential variant-proof COVID-19 vaccine, Maria Wurm, CEO of ExcellGene said.
Prof Jamie Triccas, Sydney Institute for Infectious Diseases, The University of Sydney said, "We are delighted to partner with ExcellGene, Bharat Biotech and the CEPI organisation to progress our platform for the development of broadly protective COVID-19 vaccines." The University of Sydney will provide a framework for pre-clinical assessment of vaccine candidates, together with access to Australia’s world-class early phase clinical trial community.